Search results
Five thoughts from Stars-Golden Knights: It’s on to Game 7 as Dallas held scoreless
Dallas Morning News· 8 hours agoThe Vegas Golden Knights came away with a season-saving win in Game 6 against the Dallas Stars at T...
‘He steals money’: Canelo Alvarez, Oscar De La Hoya exchange verbal jabs
Las Vegas Review-Journal· 3 days agoA war of words that has been percolating in the past few weeks bubbled over Wednesday ahead of...
Johnston scores again and Stars beat Golden Knights 4-2 in Game 4 to even series
FOX 4 News Dallas - Fort Worth· 4 days agoThe Stars' first playoff series is now tied thanks to a major win on the road Monday night. LAS...
Katt Williams Wants to Show You the Receipts
New York Times· 2 days agoAfter setting the internet aflame earlier this year when he slammed several other comedians in a viral interview, he plans to say more of what’s on his...
5 thoughts from Stars-Knights: Wyatt Johnston ends graveyard-shift Game 3 in overtime
Dallas Morning News· 6 days agoThe Stars secured their first win of the postseason in a 3-2 overtime finish against the Vegas...
35 Years Ago: STS-30 Launches Magellan to Venus - NASA
NASA· 2 days agoOn May 4, 1989, space shuttle Atlantis took off on its third flight, STS-30, from NASA’s Kennedy...
Golden Knights need to show the innate resilience they claim in Game 4
Las Vegas Sun· 5 days agoThe first time the Golden Knights flashed the near-unstoppable potential that they eventually turned...
Mariners secure series win over Braves behind more dominant pitching
Seattle Times· 3 days agoWell, that may be a little premature since the Mariners still have one more game remaining on this...
Q1 2024 PNM Resources Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 3 days agoWe are affirming our guidance for 2024 at a range of $2.65 to $2.75. We are also affirming our long-term rate base growth and earnings growth targets. Lisa will cover the ...
Q1 2024 GeneDx Holdings Corp Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 4 days agoSo our product mix this quarter is a sign of early success on this path to a to test future. We continue to drive market leadership with 80% of all clinical exomes being run at</ ...
